64 completed. 64 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 64 | Completed 64 |
Follow Conjunctivitis: new trials by email Literature Review of Conjunctivitis trials Research Report on Conjunctivitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 4 Study Evaluating the Safety of the Nasal Guide With Tyrvaya Nasal Guide - Dry Eye, Keratoconjunctivitis Sicca | Phase 4 | Completed | Oyster Point Pharma, Inc. | 30 | 2023-06-14 | 2025-05-06 |
| Clinical and Biological Evaluation of NAAGA Versus Azelastine Eye Drops in Allergic Subjects With Tear Film Dysfunction NAAGA (N-acetyl-aspartyl-glutamate) 49 mg/mL, azelastine hydrochloride 0.05% - Allergic Conjunctivitis, Dry Eye Disease (DED) | Phase 4 | Completed | Azienda Ospedaliera OO.RR. S. Giovanni di Dio e Ruggi D'Aragona | 134 | 2023-04-21 | 2025-07-15 |
| Enhancing the A in SAFE for Trachoma Azithromycin for Routine Community-wide MDA, Two Additional Rounds of Azithromycin for Children, Azithromycin for Second Community-wide MDA - Trachoma | Phase 4 | Completed | Emory University | 34630 | 2022-05-04 | 2024-02-29 |
| A Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Flonase® Allergy Relief in Subjects With Allergic Conjunctivitis olopatadine hydrochloride ophthalmic solution 0.7%), Fluticasone Propionate, Tears Naturale - Allergic Conjunctivitis | Phase 4 | Completed | Andover Research Eye Institute | 61 | 2021-12-31 | 2022-09-02 |
| A Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Claritin® Tablets 24-Hour in Subjects With Allergic Conjunctivitis olopatadine hydrochloride ophthalmic solution 0.7%, loratadine 10 mg, Tears Naturale - Allergic Conjunctivitis | Phase 4 | Completed | Andover Research Eye Institute | 58 | 2021-12-14 | 2022-05-03 |
| Cluster RCT of Co-administration Azithromycin, Albendazole & Ivermectin Administration of Albendazole on Day 1, Administration of Ivermectin on Day 1, Administration of Azithromycin on Day 1 - Trachoma, Lymphatic Filariases | Phase 4 | Completed | London School of Hygiene and Tropical Medicine | 13511 | 2021-12-01 | 2022-08-19 |
| The Effect of Upneeq (Oxymetazoline Hydrochloride 0.1%) on Eyelid Position, Eye Redness, and Eye Appearance Oxymetazoline hydrochloride 0.1% ophthalmic solution, Placebo - Ptosis, Eyelid, Conjunctiva Inflamed | Phase 4 | Completed | University of Miami | 114 | 2021-06-08 | 2023-04-24 |
| Azithromycin Reduction to Reach Elimination of Trachoma Azithromycin - Trachoma | Phase 4 | Completed | University of California, San Francisco | 3931 | 2021-05-29 | 2026-03-25 |
| Tolerability Comparison of Flarex to Lotemax SM Fluorometholone Acetate Ophthalmic Suspension 0.1%, Loteprednol Etabonate Ophthalmic Gel 0.38% - Ocular Inflammation, Keratoconjunctivitis | Phase 4 | Completed | Harrow Inc | 40 | 2021-05-01 | 2026-09-22 |
| Efficacy and Toxicity of Bepotastine 1,5% PF vs Olopatadine 0,2% With BAK on Allergic Conjunctivitis Treatment Bepotastine Besilate 1.5% PF, Olopatadine Hydrochloride 0.2% BAK - Allergic Conjunctivitis | Phase 4 | Completed | Laboratorios Poen | 97 | 2021-03-10 | 2022-12-15 |
| Effect of Cequa™ in Subjects With Dry Eye Disease CequaTM (Cyclosporine 0.09%) ophthalmic solution - Dry Eye Disease | Phase 4 | Completed | Sun Pharmaceutical Industries Limited | 135 | 2020-06-29 | 2024-02-06 |
| Antibiotic Resistance and Microbiome in Children Aged 6-59 Months in Nouna, Burkina Faso Azithromycin, Amoxicillin, Cotrimoxazole - Child Development | Phase 4 | Completed | University of California, San Francisco | 252 | 2017-07-04 | 2023-03-02 |
| Lifitegrast 5% Ophthalmic Solution and Contact Lens Dryness Lifitegrast - Contact Lens, Contact Lens Discomfort | Phase 4 | Completed | EV Clinical Trials | 21 | 2016-12-16 | 2018-09-28 |
| A Novel Combined Therapy for Refractory Vernal Keratoconjunctivitis Tacrolimus - Vernal Keratoconjunctivitis | Phase 4 | Completed | Zhongshan Ophthalmic Center, Sun Yat-sen University | 20 | 2016-11-01 | 2018-03-14 |
| A Single-Center Evaluation of the Anti-Inflammatory Effects of Lastacaft as Measured by In-Vivo Confocal Microscopy Lastacaft ®, Tears Naturale ® (Placebo) - Allergic Conjunctivitis | Phase 4 | Completed | ORA, Inc. | 25 | 2014-12-01 | 2021-03-18 |
| Mortality Reduction After Oral Azithromycin: Morbidity Study Azithromycin, Placebo - Childhood Mortality | Phase 4 | Completed | University of California, San Francisco | 72000 | 2014-11-01 | 2021-03-17 |
| A Safety and Efficacy Study of OPTIVE FUSION™ With VISMED® Multi for the Management of Dry Eye carboxymethylcellulose 0.5%/glycerin 0.9%, sodium hyaluronate 0.18% - Dry Eye Syndromes, Keratoconjunctivitis Sicca | Phase 4 | Completed | Allergan | 80 | 2014-05-14 | 2019-04-18 |
| A Phase 4 Study Investigating the Efficacy of Retaine™ in Managing Signs and Symptoms Associated With Dry Eye Syndrome Retaine™ - Keratoconjunctivitis Sicca | Phase 4 | Completed | Ocusoft, Inc. | 42 | 2014-05-01 | 2014-06-11 |
| Effectiveness of Olopatadine HCl Ophthalmic Solution for the Treatment of Allergic Conjunctivitis in Japan Olopatadine HCl ophthalmic solution, 0.1%, Epinastine HCl ophthalmic solution, 0.05% - Allergic Conjunctivitis | Phase 4 | Completed | Alcon Research | 50 | 2013-12-01 | 2015-10-07 |
| Effects of Dry Eye Treatments on the Ocular Surface Dexamethasone, Artificial tear - Keratoconjunctivitis Sicca, Dry Eye Syndrome | Phase 4 | Completed | Baylor College of Medicine | 20 | 2013-02-01 | 2020-02-05 |
Showing 20 of 64. Sign in to see all of them.
Conjunctivitis, Allergic (32) · Trachoma (14) · Dry Eye Syndromes (10) · Keratoconjunctivitis Sicca (8) · Chlamydia Infections (5) · Bacterial Infections (3) · Conjunctivitis, Bacterial (3) · Eye Diseases (2) · Infections (2) · Keratoconjunctivitis (2) · Adenoviridae Infections (1) · Asthma (1) · Blepharoptosis (1) · Conjunctivitis, Viral (1)
Conjunctival Diseases (64) · Eye Diseases (62) · Hypersensitivity (32) · Hypersensitivity, Immediate (32) · Immune System Diseases (32) · Corneal Diseases (24) · Eye Infections (18) · Bacterial Infections and Mycoses (17) · Eye Infections, Bacterial (17) · Infections (17) · Bacterial Infections (14) · Chlamydiaceae Infections (14) · Conjunctivitis, Bacterial (14) · Gram-Negative Bacterial Infections (14)
Olopatadine Hydrochloride (14) · Azithromycin (7) · Lubricant Eye Drops (7) · Ophthalmic Solutions (7) · Loteprednol Etabonate (6) · bepotastine besilate (4) · Dexamethasone (3) · Dextrans (3) · Fluticasone (3) · Moxifloxacin (3) · alcaftadine (3) · Carboxymethylcellulose Sodium (2) · Cyclosporine (2) · isospaglumic acid (2) · prednisolone acetate (2)
Alcon Research (12) · University of California, San Francisco (7) · Allergan (5) · Johns Hopkins University (4) · ORA, Inc. (4) · Andover Research Eye Institute (2) · Bausch & Lomb Incorporated (2) · Laboratoires Thea (2) · London School of Hygiene and Tropical Medicine (2) · Azienda Ospedaliera OO.RR. S. Giovanni di Dio e Ruggi D'Aragona (1) · Baylor College of Medicine (1) · EV Clinical Trials (1) · Emory University (1) · Greiner, Jack V., OD DO PhD (1) · Harrow Inc (1)
United States (36) · Ethiopia (5) · Niger (3) · South Korea (3) · United Kingdom (3) · France (2) · Italy (2) · Tanzania (2) · Argentina (1) · Burkina Faso (1) · Canada (1) · China (1) · Finland (1) · India (1) · Japan (1)
Tom Lietman, MD (3) · Kieran S O'Brien, MPH (2) · Paul Emerson, PhD (2) · Sheila K West (2) · Tarek Shazly, MD (2) · Thomas M Lietman, MD (2) · Abdou Amza, MD (1) · Adisak Trinavarat, MD (1) · Ahmad M Fahmy, O.D. (1) · Binu Alexander, MD (1) · Bob Q Lanier, MD (1) · Catherine E Oldenburg, ScD (1) · Catherine Oldenburg, ScD, MPH (1)
PMID 25260889, PMID 16905024, PMID 17585003, PMID 19127072, PMID 19302250, PMID 19329003, PMID 21072224, PMID 21685340, PMID 22095569, PMID 22180732, PMID 22192488, PMID 22545165, PMID 22736616, PMID 22953007, PMID 23326612, PMID 23392481, PMID 23785525, PMID 24433194, PMID 24621121, PMID 25002297, PMID 25083776, PMID 25407464, PMID 25858004, PMID 26302380, PMID 26489933, PMID 27956455, PMID 28351345, PMID 28402408, PMID 28893761, PMID 29088030, PMID 29260659, PMID 29561511, PMID 29897440, PMID 30014828, PMID 30106956, PMID 30151409, PMID 30419040, PMID 30515431, PMID 30689671, PMID 30895203, PMID 30950493, PMID 31166952, PMID 31237871, PMID 31362969, PMID 31589610, PMID 31796025, PMID 32556194, PMID 33407263, PMID 34559801, PMID 34967883
5UG1EY030833 (1), R01AI048789 (1)